Should biologics be used as first-line therapy in the treatment of spondyloarthritides (SpA) or are NSAIDs still the preferred option? A pro-and-con discussion explored this question at this year’s DGIM Congress.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- InFo RHEUMATOLOGIE
